Thus, EVI1 was overexpressed as compared with corresponding healthy tissues, associated with parameters reflecting disease aggressiveness, and/or correlated with shorter survival in a variety of tumor entities, including glioblastoma multiforme [20], triple negative breast cancer [21], clear cell renal cell carcinoma [22], lung squamous cell carcinoma [23], cholangiocarcinoma [24,25], prostate cancer [26], serous epithelial ovarian cancer [27], pancreatic ductal adenocarcinoma [28], and nasopharyngeal carcinoma [9]. The gene discussed is MECOM; the disease is pancreatic ductal adenocarcinoma.